Clinical Development Targeted Protein Degradation Trials 
Drug Hunter
JULY 21, 2023
semaglutide/Ozempic), this month features a pair of ultra-hot non-peptide oral GLP-1R modulators in clinical development. lirafubratinib (RLY4008) – An oral covalent FGFR2 inhibitor in Phase II trials for cholangiocarcinoma, designed through rational design and molecular dynamic simulations by Relay Therapeutics.
The Pharma Data
JULY 22, 2021
(NYSE: PFE) today announced a global collaboration to develop and commercialize ARV-471, an investigational oral PROTAC® (PROteolysis TArgeting Chimera) estrogen receptor protein degrader. The companies will equally share worldwide development costs, commercialization expenses, and profits.
Expert insights. Personalized for you.
227 
Let's personalize your content